Mostrar el registro sencillo del ítem

dc.contributor.author
Kenney, Jessica  
dc.contributor.author
Rodríguez, Aixa  
dc.contributor.author
Kizima, Larisa  
dc.contributor.author
Seidor, Samantha  
dc.contributor.author
Menon, Radhika  
dc.contributor.author
Jean Pierre, Ninochka  
dc.contributor.author
Pugach, Pavel  
dc.contributor.author
Levendosky, Keith  
dc.contributor.author
Derby, Nina  
dc.contributor.author
Gettie, Agegnehu  
dc.contributor.author
Blanchard, James  
dc.contributor.author
Piatak, Michael  
dc.contributor.author
Lifson, Jeffrey D.  
dc.contributor.author
Paglini, Maria Gabriela  
dc.contributor.author
Zydowsky, Thomas M.  
dc.contributor.author
Robbiani, Melissa  
dc.contributor.author
Fernández Romero, José A.  
dc.date.available
2017-10-31T14:50:10Z  
dc.date.issued
2013-06  
dc.identifier.citation
Kenney, Jessica; Rodríguez, Aixa; Kizima, Larisa; Seidor, Samantha; Menon, Radhika; et al.; A Modified Zinc Acetate Gel, a Potential Nonantiretroviral Microbicide, Is Safe and Effective against Simian-Human Immunodeficiency Virus and Herpes Simplex Virus 2 Infection In Vivo; American Society for Microbiology; Antimicrobial Agents and Chemotherapy; 57; 8; 6-2013; 4001-4009  
dc.identifier.issn
0066-4804  
dc.identifier.uri
http://hdl.handle.net/11336/27229  
dc.description.abstract
We previously showed that a prototype gel comprising zinc acetate (ZA) in carrageenan (CG) protected mice against vaginal and rectal herpes simplex virus 2 (HSV-2) challenge as well as macaques against vaginal simian-human immunodeficiency virus reverse transcriptase (SHIV-RT) challenge. In this work, we modified buffers and cosolvents to obtain a stable, nearly iso-osmolal formulation and evaluated its safety and efficacy against SHIV-RT and HSV-2. In vitro toxicity to lactobacilli and Candida albicans was determined. Macaques were given daily doses of ZA and CG (ZA/CG) or CG alone vaginally for 14 days and challenged with SHIV-RT 24 h later. Mice were challenged vaginally or rectally with HSV-2 immediately after a single gel treatment to measure efficacy or vaginally 12 h after daily gel treatment for 7 days to evaluate the gel's impact on susceptibility to HSV-2 infection. The modified ZA/CG neither affected the viability of lactobacilli or C. albicans nor enhanced vaginal HSV-2 infection after daily ZA/CG treatment. Vaginal SHIV-RT infection of macaques was reduced by 66% (P = 0.006) when macaques were challenged 24 h after the last dose of gel. We observed 60% to 80% uninfected mice after vaginal (P < 0.0001) and rectal (P = 0.008) high-dose HSV-2 challenge. The modified ZA/CG gel is safe and effective in animal models and represents a potential candidate to limit the transmission of HIV and HSV-2.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
American Society for Microbiology  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Microbicides  
dc.subject
Zinc Acetate  
dc.subject
Macaques  
dc.subject
Shiv-Rt  
dc.subject
Hsv-2  
dc.subject
Mouse  
dc.subject
Vaginal  
dc.subject
Rectal  
dc.subject.classification
Ética Médica  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
A Modified Zinc Acetate Gel, a Potential Nonantiretroviral Microbicide, Is Safe and Effective against Simian-Human Immunodeficiency Virus and Herpes Simplex Virus 2 Infection In Vivo  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2017-10-02T19:06:34Z  
dc.journal.volume
57  
dc.journal.number
8  
dc.journal.pagination
4001-4009  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Washington DC  
dc.description.fil
Fil: Kenney, Jessica. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Rodríguez, Aixa. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Kizima, Larisa. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Seidor, Samantha. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Menon, Radhika. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Jean Pierre, Ninochka. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Pugach, Pavel. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Levendosky, Keith. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Derby, Nina. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Gettie, Agegnehu. The Rockefeller University; Estados Unidos  
dc.description.fil
Fil: Blanchard, James. University of Tulane; Estados Unidos  
dc.description.fil
Fil: Piatak, Michael. Frederick National Laboratory for Cancer Research; Estados Unidos  
dc.description.fil
Fil: Lifson, Jeffrey D.. Frederick National Laboratory for Cancer Research; Estados Unidos  
dc.description.fil
Fil: Paglini, Maria Gabriela. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología; Argentina  
dc.description.fil
Fil: Zydowsky, Thomas M.. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Robbiani, Melissa. Center for Biomedical Research; Estados Unidos  
dc.description.fil
Fil: Fernández Romero, José A.. Center for Biomedical Research; Estados Unidos. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología; Argentina  
dc.journal.title
Antimicrobial Agents and Chemotherapy  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1128/AAC.00796-13  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://aac.asm.org/content/57/8/4001  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719770/